

Abdurrahman Mithat Bozdayi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3729128/publications.pdf>

Version: 2024-02-01

71
papers

1,861
citations

257357

24
h-index

276775

41
g-index

71
all docs

71
docs citations

71
times ranked

2271
citing authors

#	ARTICLE	IF	CITATIONS
1	Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDVâ€ study. <i>Hepatology</i> , 2018, 67, 1224-1236.	3.6	117
2	A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitisâ€ end of treatment results from the LOWR HDV-2 study. <i>Journal of Hepatology</i> , 2017, 66, S33-S34.	1.8	38
3	Discontinuation of Lamivudine Treatment in HBeAg-Negative Chronic Hepatitis B: A Pilot Study with Long-Term follow-up. <i>Antiviral Therapy</i> , 2017, 22, 559-570.	0.6	7
4	Investigation of West Nile virus among healthy blood donors in the western part of Turkey. <i>Turkish Journal of Medical Sciences</i> , 2015, 45, 84-88.	0.4	10
5	Interleukinâ€28 gene polymorphisms may contribute to <sc>HB</sc>sAg persistence and the development of <sc>HB</sc>eAgâ€negative chronic hepatitis B. <i>Liver International</i> , 2015, 35, 846-853.	1.9	20
6	Tumour necrosis factorâ€alpha, interleukinâ€10, interferonâ€gamma and vitamin <sc>D</sc> receptor gene polymorphisms in patients with chronic hepatitis delta. <i>Journal of Viral Hepatitis</i> , 2014, 21, 297-304.	1.0	17
7	A one step real time PCR method for the quantification of hepatitis delta virus RNA using an external armored RNA standard and intrinsic internal control. <i>Journal of Clinical Virology</i> , 2014, 60, 11-15.	1.6	19
8	Role of immunohistochemistry for hepatitis D and hepatitis B virus in hepatitis delta. <i>Liver International</i> , 2014, 34, 1207-1215.	1.9	7
9	Free circulating nucleic acids in plasma and serum as a novel approach to the use of internal controls in real time PCR based detection. <i>Journal of Virological Methods</i> , 2014, 207, 133-137.	1.0	9
10	Efficacy of tenofovir in adefovir-experienced patients compared to treatment-naive patients with chronic hepatitis B. <i>Antiviral Therapy</i> , 2014, 19, 543-550.	0.6	11
11	Hepatitis C virus genotype distribution in Turkey remains unchanged after a decade: Performance of phylogenetic analysis of the NS5B, E1, and 5â€UTR regions in genotyping efficiency. <i>Turkish Journal of Gastroenterology</i> , 2014, 25, 405-410.	0.4	16
12	Clonal Analysis of the Quasispecies of Antiviral-Resistant HBV Genomes in Patients with Entecavir Resistance during Rescue Treatment and Successful Treatment of Entecavir Resistance with Tenofovir. <i>Antiviral Therapy</i> , 2013, 18, 77-85.	0.6	12
13	Importance of Serum SELDI-TOF-MS Analysis in the Diagnosis of Early Lung Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013, 14, 2037-2042.	0.5	13
14	Entecavir Treatment of Chronic Hepatitis D. <i>Clinical Infectious Diseases</i> , 2012, 55, 645-650.	2.9	50
15	Isolation of biliary lipid carrying vesicles, analysis of their biochemical properties and hepatic ABCG5 mRNA expression in diosgenin-fed rats. <i>Turkish Journal of Biochemistry</i> , 2012, 37, 167-174.	0.3	0
16	The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country. <i>European Journal of Health Economics</i> , 2012, 13, 663-676.	1.4	24
17	<sc>HB</sc>eAgâ€positive hepatitis delta: virological patterns and clinical longâ€term outcome. <i>Liver International</i> , 2012, 32, 1415-1425.	1.9	52
18	Molecular characterization of a novel entecavir mutation pattern isolated from a multi-drug refractory patient with chronic hepatitis B infection. <i>Journal of Clinical Virology</i> , 2012, 53, 130-134.	1.6	16

#	ARTICLE	IF	CITATIONS
19	Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients. <i>Journal of Viral Hepatitis</i> , 2012, 19, 220-226.	1.0	28
20	Potential proteomic biomarkers in assessing liver fibrosis using SELDI-TOF MS. <i>Turkish Journal of Gastroenterology</i> , 2012, 23, 46-53.	0.4	4
21	Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis. <i>Turkish Journal of Gastroenterology</i> , 2012, 23, 560-568.	0.4	22
22	Evaluation of Relationship Between Serum Protein Profiles and Lung Cancer by SELDI-TOF-MS (Surface) Tj ETQq0 0 0 rgBT /Overlock 10 <i>Journal of Medical Sciences</i> , 2012, 32, 1084-1089.	0.1	0
23	Effect of Turkish propolis extracts on proteome of prostate cancer cell line. <i>Proteome Science</i> , 2011, 9, 74.	0.7	46
24	Complete genome sequences and phylogenetic analysis of hepatitis delta viruses isolated from nine Turkish patients. <i>Archives of Virology</i> , 2011, 156, 2215-2220.	0.9	18
25	Serum connective tissue markers as predictors of advanced fibrosis in patients with chronic hepatitis B and D. <i>Turkish Journal of Gastroenterology</i> , 2011, 22, 305-314.	0.4	18
26	A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients. <i>Journal of Viral Hepatitis</i> , 2009, 16, 279-285.	1.0	19
27	Treatment of chronic delta hepatitis with lamivudine + interferon. <i>Journal of Viral Hepatitis</i> , 2008, 15, 314-321.	1.0	115
28	Antimicrobial and Antiviral Screening of Novel Indole Carboxamide and Propanamide Derivatives. <i>Zeitschrift Fur Naturforschung - Section C Journal of Biosciences</i> , 2008, 63, 189-195.	0.6	25
29	A pilot study of 2 years of interferon treatment in patients with chronic delta hepatitis. <i>Journal of Viral Hepatitis</i> , 2007, 14, 812-816.	1.0	61
30	Inhibition of hepatitis B virus replication by shRNAs in stably HBV expressed HEPG2 2.2.15 cell lines. <i>Archives of Virology</i> , 2007, 152, 871-879.	0.9	11
31	Pegylated interferon-alpha plus taurine in treatment of rat liver fibrosis. <i>World Journal of Gastroenterology</i> , 2007, 13, 3237.	1.4	30
32	Cutaneous, pulmonary and hepatic sarcoidosis associated with autoimmune complications during interferon-alpha treatment for hepatitis C virus infection. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2006, 20, 442-445.	1.3	13
33	Cytotoxic CD4+ T cells in viral hepatitis. <i>Journal of Viral Hepatitis</i> , 2006, 13, 505-514.	1.0	130
34	NOD2/CARD15, NOD1/CARD4, and ICAM-1 gene polymorphisms in Turkish patients with inflammatory bowel disease. <i>Journal of Gastroenterology</i> , 2006, 41, 304-310.	2.3	49
35	Trefoil Factor Expression in Biliary Epithelium of Graft-versus-Host Disease of the Liver after Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation</i> , 2005, 80, 1099-1104.	0.5	3
36	Thrombophilic gene mutations in cirrhotic patients with portal vein thrombosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2005, 17, 339-343.	0.8	62

#	ARTICLE	IF	CITATIONS
37	Lamivudine vs lamivudine and interferon combination treatment of HBeAg(-) chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2005, 12, 262-268.	1.0	34
38	Fatigue of cholestasis and the serotonergic neurotransmitter system in the rat. <i>Hepatology</i> , 2005, 41, 731-737.	3.6	24
39	Complete genome sequence and phylogenetic analysis of hepatitis B virus isolated from turkish patients with chronic HBV infection. <i>Journal of Medical Virology</i> , 2005, 76, 476-481.	2.5	61
40	Emergence of a Novel Mutation in the FLLA Region of Hepatitis B Virus during Lamivudine Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 2618-2624.	1.4	11
41	Screening for Hemochromatosis in Turkey. <i>Digestive Diseases and Sciences</i> , 2004, 49, 444-449.	1.1	13
42	Molecular epidemiology of hepatitis B, C and D viruses in Turkish patients. <i>Archives of Virology</i> , 2004, 149, 2115-2129.	0.9	93
43	Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies. <i>Journal of Viral Hepatitis</i> , 2004, 11, 141-147.	1.0	80
44	A novel pattern (sW195a) in surface gene of HBV DNA due to YSDD (L180M plus M204S) mutation selected during lamivudine therapy and successful treatment with adefovir dipivoxil. <i>Journal of Clinical Virology</i> , 2004, 31, 76-77.	1.6	7
45	Late Failure of Combined Recombinant Hepatitis B Vaccine and Lamivudine in Treatment of a Patient with Chronic Hepatitis B. <i>Southern Medical Journal</i> , 2004, 97, 407-409.	0.3	0
46	Interferon-alpha2b induction treatment with or without ribavirin in chronic hepatitis C: a multicenter, randomized, controlled trial. <i>Digestive Diseases and Sciences</i> , 2003, 48, 1124-1129.	1.1	7
47	YSDD: a novel mutation in HBV DNA polymerase confers clinical resistance to lamivudine. <i>Journal of Viral Hepatitis</i> , 2003, 10, 256-265.	1.0	50
48	The role of HBeAg seroconversion in acute exacerbation of liver disease with termination of hepatitis B and D virus infection in a chronic hepatitis D patient during ??-interferon therapy. <i>European Journal of Gastroenterology and Hepatology</i> , 2003, 15, 819-823.	0.8	0
49	The role of HBeAg seroconversion in acute exacerbation of liver disease with termination of hepatitis B and D virus infection in a chronic hepatitis D patient during Î±-interferon therapy. <i>European Journal of Gastroenterology and Hepatology</i> , 2003, 15, 819-823.	0.8	7
50	Screening for Iron Overload in the Turkish Population. <i>Digestive Diseases</i> , 2003, 21, 279-285.	0.8	12
51	Oral Ganciclovir for Treatment of Lamivudineâ€Resistant Hepatitis B Virus Infection: A Pilot Study. <i>Clinical Infectious Diseases</i> , 2002, 35, 960-965.	2.9	8
52	Famciclovir treatment of chronic delta hepatitis. <i>Journal of Hepatology</i> , 2002, 37, 266-271.	1.8	103
53	Lamivudine is not effective in the treatment of non-cirrhotic HBeAg (âˆ™) chronic hepatitis B patients with low level viremia. <i>Journal of Hepatology</i> , 2002, 36, 100.	1.8	0
54	Predictive value of ALT and HBV DNA levels in response to sequential combination treatment of lamivudine and interferon in HBeAgâ€/ANTI-Hbe+ chronic hepatitis B. <i>Journal of Hepatology</i> , 2002, 36, 104.	1.8	0

#	ARTICLE	IF	CITATIONS
55	Ganciclovir treatment of lamivudine-resistant HBV infection. <i>Journal of Hepatology</i> , 2002, 36, 229-230.	1.8	0
56	Long term follow up chronic hepatitis B patients treated with interferon. <i>Journal of Hepatology</i> , 2002, 36, 241.	1.8	0
57	Screening for hemochromatosis in Turkey. <i>Journal of Hepatology</i> , 2002, 36, 254-255.	1.8	34
58	Bronchoalveolar lavage fluid analysis in individuals with chronic hepatitis C. <i>Journal of Medical Virology</i> , 2002, 66, 34-39.	2.5	34
59	Remission of severe aplastic anemia associated with hepatitis B virus infection after viral clearance: potential role of lamivudine. <i>Digestive Diseases and Sciences</i> , 2002, 47, 1782-1785.	1.1	14
60	Nucleotide divergences in the core promoter and precore region of genotype D hepatitis B virus in patients with persistently elevated or normal ALT levels. <i>Journal of Clinical Virology</i> , 2001, 21, 91-101.	1.6	31
61	Circulating IL-2 and IL-10 in Chronic Active Hepatitis C with Respect to the Response to IFN Treatment. <i>Infection</i> , 2000, 28, 309-313.	2.3	14
62	Prevalence of hepatitis-G virus and hepatitis-C virus infection in patients with non-Hodgkin's lymphoma. <i>Medical Oncology</i> , 2000, 17, 123-126.	1.2	20
63	Influence of Viral Load and Alanine Aminotransferase on Viral Genetic Heterogeneity in Patients with Chronic Hepatitis C Virus Infection. <i>Intervirology</i> , 2000, 43, 61-66.	1.2	4
64	Arachidonic acid metabolites as biocompatibility parameters for cellulosic membranes. <i>Nephrology Dialysis Transplantation</i> , 1999, 14, 1804-1805.	0.4	0
65	Serum cytotoxin and oxidant stress markers in N-acetylcysteine treated thioacetamide hepatotoxicity of rats. <i>Human and Experimental Toxicology</i> , 1999, 18, 669-676.	1.1	38
66	Polymorphism of Precore Region of Hepatitis B Virus DNA among Patients with Chronic HBV Infection in Turkey. <i>Infection</i> , 1999, 27, 357-360.	2.3	21
67	Influence of Two Blood Conservation Techniques (Cardiotomy Reservoir Versus Cell-Saver) on Biocompatibility of the Heparin Coated Cardiopulmonary Bypass Circuit During Coronary Revascularization Surgery. <i>Journal of Cardiac Surgery</i> , 1997, 12, 190-197.	0.3	14
68	Effects of Heparin Coating of Cardiopulmonary Bypass Circuits on In Vitro Oxygen Free Radical Production During Coronary Bypass Surgery. <i>Artificial Organs</i> , 1996, 20, 1008-1016.	1.0	15
69	The beneficial effects of aminophylline administration on heparin reversal with protamine. <i>Surgery Today</i> , 1994, 24, 99-102.	0.7	8
70	Beneficial Effects of Prostacyclin on Pulmonary Function During Heparin Reversal with Protamine. <i>Vascular Surgery</i> , 1993, 27, 264-267.	0.3	0
71	Effects of Prostacyclin on Heparin Reversal with Protamine. <i>Vascular Surgery</i> , 1992, 26, 464-473.	0.3	12